Vali Mohebat, Maleki Zahra, Jahani Mohammad-Ali, Nazemi Sina, Ghelichi-Ghojogh Mousa, Hassanipour Soheil, Javanian Mostafa, Nikbakht Hossein-Ali
Non-Communicable Diseases Research Center, Research Center for Health Sciences, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran.
Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
Caspian J Intern Med. 2025 Mar 11;16(2):215-224. doi: 10.22088/cjim.16.2.215. eCollection 2025.
Uterine cancer ranks among the leading causes of mortality in women, particularly prevalent in countries with low to moderate income levels. Present treatment and healthcare success rates are assessed by the survival rate index. This study aimed to determine the uterine cancer survival rate in Asia.
Five international databases were analyzed to perform this systematic review: Medline/PubMed, ProQuest, Scopus, Web of Knowledge, and Google Scholar, until the end of August 2021. The Newcastle-Ottawa quality assessment form was utilized in the evaluation of quality for cohort studies. "I2 statistic and Cochran test were used to check the analysis process and assess the heterogeneity among the studies. Also, the study year was used as the basis for a meta-regression analysis.
The study covered 75 papers in total. The survival rates of uterine cancer after one, three, five, and seven years are 76.68% (95% CI, 66.76-78.61), 63.56% (95% CI, 58.60-68.37), 59.04% (95% CI, 55.62-62.43), and 57.86% (95% CI, 51.16-64.42) according to the random model. Furthermore, according to the outcomes of the meta-regression, there was no correlation found between the study year and the survival rate.
Compared to European and American countries, Asian countries have a poorer uterine cancer survival rate, which makes it crucial to improve the survival rate of patients through ensuring early diagnosis of the disease in its early stages and providing new diagnostic methods, modified surgical techniques, and targeted therapies.
子宫癌是女性主要死因之一，在中低收入国家尤为普遍。目前的治疗方法和医疗成功率通过生存率指数进行评估。本研究旨在确定亚洲子宫癌的生存率。
分析了五个国际数据库以进行这项系统评价：Medline/PubMed、ProQuest、Scopus、Web of Knowledge和谷歌学术，直至2021年8月底。纽卡斯尔-渥太华质量评估表用于队列研究的质量评估。使用“I2统计量和 Cochr an检验来检查分析过程并评估研究之间的异质性。此外，研究年份用作meta回归分析的基础。
该研究共涵盖75篇论文。根据随机模型，子宫癌1年、3年、5年和7年后的生存率分别为76.68%（95%CI，66.76 - 78.61）、63.56%（95%CI，58.60 - 68.37）、59.04%（95%CI，55.62 - 62.43）和57.86%（95%CI，51.16 - 64.42）。此外，根据meta回归结果，未发现研究年份与生存率之间存在相关性。
与欧美国家相比，亚洲国家子宫癌生存率较低，因此通过确保疾病早期诊断、提供新的诊断方法、改进手术技术和靶向治疗来提高患者生存率至关重要。
